Biovica announced this morning an expanded work order within its Pharma Services division from a clinical-stage biopharmaceutical company. The unnamed client, currently developing a next-generation CDK inhibitor for solid tumors, is expanding the collaboration after seeing promising initial TKa biomarker findings in its ongoing Phase I program.
LÄS MER
